ERBB2 overexpression (scores of 2+ and 3+) according to the ASCO/CAP 2018 guidelines in BC was seen in zero, two, and thirteen UTUCs, with WHO grades of 1, 2, or 3, respectively. Here, ERBB2 is linked to breast cancer.